Cipla Recalls Cinacalcet Hydrochloride Tablets Over Impurity Risk
Cipla USA, Inc. recalled 63,504 bottles of Cinacalcet Hydrochloride Tablets on November 14, 2025. The recall results from a nitrosamine impurity, N-nitroso-cinacalcet, exceeding acceptable daily intake limits. Consumers should stop using the tablets immediately and contact healthcare providers for guidance.
Quick Facts at a Glance
Recall Date
November 14, 2025
Hazard Level
HIGH
Brands
CINACALCET, Cipla USA Inc.
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL
Hazard Information
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
What You Should Do
Consumers and healthcare providers should stop using this product immediately. Contact Cipla USA, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
No spamUnsubscribe anytime
About This Product
Cinacalcet Hydrochloride Tablets are used to treat conditions related to elevated parathyroid hormone levels, often prescribed for patients with chronic kidney disease or hyperparathyroidism. Patients buy these tablets for their potential to manage calcium and phosphorus levels in the body effectively.
Why This Is Dangerous
The recall is due to the presence of N-nitroso-cinacalcet, a nitrosamine impurity, which exceeds acceptable levels. Nitrosamines can form during the manufacturing process and have been linked to cancer risk.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
Consumers must stop using the product immediately due to the potential health risks associated with nitrosamine exposure. This may lead to inconvenience as patients seek alternatives or consult their healthcare providers.
Practical Guidance
How to identify if yours is affected
Check the bottle for the lot numbers: 4PB0109 or 5PB0172.
Verify the expiry dates: 1/31/2026 or 1/31/2027.
If you have purchased Cinacalcet Hydrochloride Tablets, confirm your product matches the recalled lots.
Where to find product info
Lot numbers and expiration dates are typically printed on the label or the bottom of the bottle.
What timeline to expect
Expect a refund or replacement to be processed within 4-6 weeks after returning the product.
If the manufacturer is unresponsive
Keep records of your communication with the company.
Reach out again, or escalate your inquiry to a consumer protection agency.
How to prevent similar issues
Always check for recalls before using prescription medications.
Consult your physician about potential alternatives if a recall occurs.
Documentation advice
Document your purchase by keeping receipts and any correspondence with the manufacturer regarding the recall.
Product Details
The recall involves Cinacalcet Hydrochloride Tablets, 30 mg, sold in bottles of 30 tablets. The affected lot numbers are 4PB0109 (expiry 1/31/2026) and 5PB0172 (expiry 1/31/2027). These tablets were distributed nationwide in the U.S.
Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.
Mazda North American Operations recalls 2025 Mazda CX-70 plug-in hybrids as software issues in the inverter may cause the malfunction indicator lights to illuminate and a loss of drive power in EV mode. Dealers will update inverter software at no cost. Letters were mailed December 19, 2024.
Mazda North American Operations recalls certain 2024-2025 CX-90 and 2025 CX-70 vehicles with a Dash ESU due to startup function failures. Software reprogramming will remedy the issue at no charge. Owner notices were mailed December 18, 2024. Contact Mazda at 1-800-222-5500 Option 6. NHTSA ID 24V814000.
Subaru recalls 2025 Forester vehicles due to potentially loose child seat anchor bolts. Dealers will inspect and tighten bolts at no charge. Owner letters are expected August 15, 2025. Contact Subaru at 1-844-373-6614. Recall number WRC-25.
Nissan recalls 2025 Pathfinder, Murano and INFINITI QX60 for front brake caliper weakness that could fail. Dealers will inspect and replace calipers as needed, free of charge. Letters sent May 9, 2025. Contact Nissan or INFINITI for remedies.
Mazda North American Operations is recalling 2025 CX-50 Hybrid and CX-50 SUVs sold through Mazda dealers. Incorrectly configured restraint-control software may cause the air bag to deploy improperly. Owner notification letters are expected to be mailed August 17, 2025.
Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.
BMW recalls 2025-2026 X1 and X2 models plus MINI Cooper and Countryman variants for front seat belt retractors with damaged torsion bars. The defect may fail to restrain occupants in a crash. Dealers will replace both front retractors at no cost. Owner letters begin November 7, 2025. VIN lookup will be available on NHTSA.gov the same day.